TEL AVIV, Israel, May 30, 2023 /PRNewswire/ -- BioLight (TASE: BOLT) is proud to report it has signed a research collaboration agreement with Alexion (AstraZeneca Rare Disease), focusing on exploring ...
* Reported results from feasibility clinical study designed to detect prostate cancer cells in urine specimens Sign up here. * Study demonstrated feasibility of detecting intact cells originating in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results